Hot Features
Premium
Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
Low
0.88
High
1.95
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Reunion Neuroscience Inc | REUN | Toronto | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.42 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.42 | 1.42 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.88 - 1.95 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.42 | CAD |
Reunion Neuroscience Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 16.64M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Reunion Neuroscience News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/03/2024 | 06:30 | GlobeNewswire Inc. | Reunion Neuroscience Inc. Announces Upcoming Presentations.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REUN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 1.28 | 1.95 | 0.88 | 1.42 | 15,954 | 0.14 | 10.94% |
| 3 Years | 5.34 | 9.44 | 0.83 | 2.11 | 10,611 | -3.92 | -73.41% |
| 5 Years | 5.34 | 9.44 | 0.83 | 2.11 | 10,611 | -3.92 | -73.41% |
Reunion Neuroscience Description
| Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. |
